发布时间：2026-03-05 15:05 Ad hoc announcement pursuant to Art. 53 LR



ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025.


Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1basis, primarily driven by volume.

Broad-based net sales growth, growing double-digits in both International markets and the U.S.

Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency.

Strong launch momentum across future growth drivers,including Nemluvio®(nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperf
=*=*=*=*=*=
当前为第1/55页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页